Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical Trial.

Autor: Cervantes-Pérez LA; Department of Hematology, Hospital Civil de Guadalajaras 'Fray Antonio Alcalde', Guadalajara 44280,, Mexico., Cervantes-Guevara G; Department of Welfare and Sustainable Development, Centro Universitario del Norte, Universidad de Guadalajara, Colotlán 46200, Mexico.; Department of Gastroenterology, Hospital Civil de Guadalajara 'Fray Antonio Alcalde', Guadalajara 44280, Mexico., Cervantes-Pérez E; Department of Internal Medicine, Hospital Civil de Guadalajara 'Fray Antonio Alcalde', Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44280, Mexico.; Centro Universitario de Tlajomulco, University of Guadalajara, Tlajomulco de Zúñiga 45641, Mexico., Cervantes-Cardona GA; Department of Philosophical, Methodological and Instrumental Disciplines, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico., Nápoles-Echauri A; Department of Philosophical, Methodological and Instrumental Disciplines, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico., González-Ojeda A; Biomedical Research Unit 02, Specialties Hospital of the Western National Medical Center, Mexican Institute of Social Security, Guadalajara 44329, Mexico., Fuentes-Orozco C; Biomedical Research Unit 02, Specialties Hospital of the Western National Medical Center, Mexican Institute of Social Security, Guadalajara 44329, Mexico., Cervantes-Pérez G; Department of Internal Medicine, Hospital Civil de Guadalajara 'Fray Antonio Alcalde', Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44280, Mexico., Reyes-Torres CA; School of Health Sciences, Instituto Tecnológico y de Estudios Superiores de Monterrey, Mexico City 14380, Mexico., Hernández-Mora FJ; Human Reproduction, Growth and Child Development Clinic, Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44340, Mexico., Ron-Magaña AL; Department of Hematology, Hospital Civil de Guadalajaras 'Fray Antonio Alcalde', Guadalajara 44280,, Mexico., Vázquez-Beltrán JC; School of Medicine, Instituto Politécnico Nacional, Mexico City 11340, Mexico., Hernández-Rivas MI; Departament of Odontology for the Preservation of Health, Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44280, Mexico., Ramírez-Ochoa S; Department of Internal Medicine, Hospital Civil de Guadalajara 'Fray Antonio Alcalde', Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44280, Mexico.
Jazyk: angličtina
Zdroj: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2023 Jun 11; Vol. 59 (6). Date of Electronic Publication: 2023 Jun 11.
DOI: 10.3390/medicina59061122
Abstrakt: Objective: We aimed to evaluate the efficacy of the combination of atorvastatin and N-acetyl cysteine in increasing platelet counts in patients with immune thrombocytopenia who were resistant to steroid therapy or had a relapse after treatment. Material and Methods : The patients included in this study received oral treatment of atorvastatin at a dose of 40 mg daily and N-acetyl cysteine at a dose of 400 mg every 8 h. The desired treatment duration was 12 months, but we included patients who completed at least 1 month of treatment in the analysis. The platelet counts were measured prior to the administration of the study treatment and in the first, third, sixth, and twelfth months of treatment (if available). A p value < 0.05 was considered statistically significant. Results : We included 15 patients who met our inclusion criteria. For the total treatment duration, the global response was 60% (nine patients); eight patients (53.3%) had a complete response and one patient (6.7%) had a partial response. Six patients (40%) were considered as having undergone treatment failure. Of the responder group, five patients maintained a complete response after treatment (55.5%), three patients maintained a partial response (33.3%), and one patient (11.1%) lost their response to the treatment. All of the patients in the responder group had significant increases in their platelet counts after treatment ( p < 0.05). Conclusion : This study provides evidence of a possible treatment option for patients with primary immune thrombocytopenia. However, further studies are needed.
Databáze: MEDLINE
Externí odkaz: